IRIS
FOGARI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.917
AS - Asia 2.239
EU - Europa 1.994
SA - Sud America 200
AF - Africa 29
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.383
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.866
CN - Cina 1.399
IE - Irlanda 492
SG - Singapore 468
UA - Ucraina 432
DE - Germania 265
FI - Finlandia 264
HK - Hong Kong 219
RU - Federazione Russa 205
BR - Brasile 168
SE - Svezia 123
IT - Italia 86
GB - Regno Unito 55
VN - Vietnam 49
CA - Canada 36
IN - India 20
FR - Francia 19
ZA - Sudafrica 16
AR - Argentina 13
ES - Italia 11
JP - Giappone 10
TR - Turchia 10
BD - Bangladesh 9
MX - Messico 8
PL - Polonia 8
AL - Albania 7
NL - Olanda 7
UZ - Uzbekistan 6
IQ - Iraq 5
IR - Iran 5
PK - Pakistan 5
BE - Belgio 4
CL - Cile 4
CO - Colombia 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
EC - Ecuador 3
IL - Israele 3
JO - Giordania 3
KG - Kirghizistan 3
MA - Marocco 3
PH - Filippine 3
RO - Romania 3
VE - Venezuela 3
AT - Austria 2
AZ - Azerbaigian 2
BH - Bahrain 2
EG - Egitto 2
ET - Etiopia 2
GE - Georgia 2
HU - Ungheria 2
ID - Indonesia 2
LB - Libano 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
AU - Australia 1
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EU - Europa 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
KE - Kenya 1
KW - Kuwait 1
KZ - Kazakistan 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MY - Malesia 1
NI - Nicaragua 1
PA - Panama 1
PT - Portogallo 1
PY - Paraguay 1
QA - Qatar 1
RS - Serbia 1
TH - Thailandia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
ZW - Zimbabwe 1
Totale 7.383
Salva come PNG Salva come JPEG
Città #
Jacksonville 537
Dublin 492
Chandler 444
Nanjing 344
Dallas 263
Hong Kong 219
Singapore 180
Ashburn 176
Boardman 162
Beijing 159
Nanchang 157
Shenyang 120
Hebei 117
Princeton 102
Wilmington 102
Lawrence 98
Changsha 97
Medford 94
Jiaxing 72
Los Angeles 72
Hangzhou 70
Tianjin 59
Helsinki 48
Buffalo 38
Redondo Beach 33
Seattle 29
Moscow 27
Munich 23
Shanghai 23
Toronto 22
New York 21
São Paulo 19
Turku 19
Woodbridge 19
Brooklyn 17
Milan 17
Hanoi 15
Ho Chi Minh City 15
Norwalk 15
Johannesburg 14
Fairfield 12
Stockholm 10
Ann Arbor 9
Belo Horizonte 9
Charlotte 9
Des Moines 9
Genova 9
Jinan 9
London 9
Orem 9
Boston 8
Bruino 8
Kunming 8
San Francisco 8
Tokyo 8
Atlanta 7
Denver 7
Phoenix 7
Santa Clara 7
Montreal 6
Ningbo 6
Secaucus 6
Washington 6
Ankara 5
Chennai 5
Guangzhou 5
Lanzhou 5
Pune 5
Tirana 5
Warsaw 5
Alcobendas 4
Brussels 4
Eindhoven 4
Frankfurt am Main 4
Kochi 4
Lima 4
Rio de Janeiro 4
São Bernardo do Campo 4
Tashkent 4
Verona 4
Amman 3
Bishkek 3
Bogotá 3
Bologna 3
Bruchsal 3
Changchun 3
Chicago 3
Curitiba 3
Franca 3
Fuzhou 3
Haiphong 3
Mexico City 3
Newark 3
Nuremberg 3
Osasco 3
Saint Petersburg 3
Shijiazhuang 3
Zhengzhou 3
Addis Ababa 2
Baghdad 2
Totale 4.869
Salva come PNG Salva come JPEG
Nome #
A randomized, placebo-controlled study about the effect of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters 186
A possible way to improve the glycemic control and the beta cell function during three years: the triple therapy. 141
A multicenter, randomised, single-blind study on the effects of exenatide or glimepiride on insulin resistance. 136
A comparison between sitagliptin or glibenclamide in addition to metformin+pioglitazone on glycemic control and beta-cell function: the triple oral therapy 123
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome 115
A randomized, double blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. 114
Different actions of losartan and ramipril on adipose tissue Activity and vascular remodeling biomarkers in hypertensive patients 110
Differential effect of candesartan and olmesartan on adipose tissue activity biomarkers in type 2 diabetic hypertensive patients 105
Effects of berberis aristata/silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients 102
A randomized, double blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetic patients already treated with pioglitazone and metformin: a three years study 102
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial 101
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients 100
Adipocytokines levels in obese and non-obese subjects, an observational study 100
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 99
Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients 99
Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus 97
Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome 95
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 92
Berberis aristata/silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients 91
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone 90
n-3 PUFAs on metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients after euglycemic clamp and oral fat load. 90
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 86
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients 83
Doxazosin improves blood pressure and metabolic parameters in impaired glucose tolerance patients in therapy with acarbose 83
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial 82
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 81
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. 81
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 81
Efficacia e sicurezza di pioglitazone o rosiglitazone in combinazione con metformina in pazienti con diabete di tipo 2 e sindrome metabolica 79
Vildagliptin added to metformin on β-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. 78
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation 78
Valutazione dei livelli di metalloproteasi 2 e 9 e dei loro inibitori nei soggetti con dislipidemia combinata 78
Effetti di un carico lipidico orale sui marcatori di rimodellamento vascolare nei soggetti sani 76
Olmesartan/amlodipine combination vs olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients 76
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia during omega-3 polyunsaturated fatty acids therapy 75
Sitagliptin in aggiunta alla precedente terapia ipoglicemizzante sull'insulino-resistenza e il profilo lipidico: uno studio a due anni 75
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 74
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load 74
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 74
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients 73
Impact of the glyco-metabolic control on erectile dysfunction in patients with type 2 diabetes mellitus 73
Effetti di un carico lipidico orale sui marcatori di infiammazione e stress endoteliale nei soggetti sani 73
Efficacia e sicurezza del pioglitazone o rosiglitazone in combinazione con metformina su pazienti diabetici dislipidemici 73
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. 73
Variation of some inflammatory markers in hypertensive patients after one year of olmesartan/amlodipine single pill combination compared to olmesartan or amlodipine monotherapies. 72
Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes 71
Moxonidine action on glucose and lipid metabolism in hypertensive patients with metabolic syndrome 71
Effetti di sitagliptin rispetto a glibenclamide in aggiunta a metformina e pioglitazone in pazienti diabetici di tipo 2 71
Exenatide or glimepiride on insulin resistance in type 2 diabetic patients 70
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 70
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone: a double-blind, randomised clinical trial 70
Effect of valsartan on insulin sensitivity, leptin, and BMI in hypertensive obese patients 70
Pioglitazone paragonato a glibenclamide sul profilo lipidico e i parametri infiammatori nei pazienti diabetici di tipo 2 in terapia con metformina durante un carico orale di grassi 70
Valutazione endocrino-metabolica di una popolazione di pazienti obesi e confronto con soggetti normopeso 70
Efficacy of simvastatin and fenofibrate association in hypercholesterolemic, type 2 diabetic patients compared to monotherapy 70
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 70
Comparison of vildagliptin and glimepiride: effects on glycemic control, fat tolerance, and inflammatory markers in people with type 2 diabetes 69
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 68
Valutazione dei livelli delle metalloproteasi 2 e 9 e dei loro inibitori nella dislipidemia combinata durante terapia con acidi grassi polinsaturi 68
Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients 68
Variation of some inflammatory biomarkers after the addition of sitagliptin in type 2 diabetic patients not controlled by metformin 68
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type2 diabetic patients not well controlled by metformin 68
Modificazioni ultrasonografiche del tessuto adiposo viscerale e sottocutaneo dopo terapia con pioglitazone o glibenclamide in combinazione con rosuvastatina in pazienti diabetici di tipo 2 non ben controllati da metformina 68
Vildagliptin action on some adipocytokines levels in type 2 diabetic patients: a 12 months, placebo-controlled study 67
Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients 67
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 66
Exenatide paragonato a glimepiride in aggiunta a metformina sul controllo glicemico, l’insulino-resistenza e i parametri infiammatori in pazienti diabetici di tipo 2 66
Exenatide plus metformin compared to metformin alone on beta cell function in type 2 diabetic patients. 65
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients 64
Effetti di una combinazione di vildagliptin + metformina su alcuni parametri di funzionalità β-cellulare e di insulino-resistenza in uno studio a 12 mesi 64
Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study 64
Matrix metalloproteinase-2, -9, and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy 64
Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared to olmesartan or amlodipine monotherapies 63
Effetti di exenatide in combinazione con metformina sulla funzione beta-cellulare in pazienti affetti da diabete mellito di tipo 2 63
Effetti di acarbose sui parametri infiammatori e di insulino-resistenza durante un carico orale di grassi 63
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: A randomized placebo-controlled trial 63
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. 63
Effetti di pioglitazone paragonato a glibenclamide sul profilo lipidico e i parametri infiammatori nei pazienti diabetici di tipo 2 in terapia con metformina dopo un carico orale di grassi 62
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 61
Una possibilità per migliorare il controllo glicemico e la funzionalità β-celllare durante tre anni di studio: la triplice terapia 61
Pioglitazone o rosiglitazone in associazione con metformina nei pazienti con diabete mellito di tipo 2 e sindrome metabolica: effetto sui fattori di rischio cardiovascolare convenzionali e non convenzionali 60
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation 60
Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction 59
Studio randomizzato, in doppio cieco, placebo-controllato sugli effetti di sitagliptin sui parametri di insulino-resistenza e di funzionalità beta-cellulare. 58
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation 58
Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies 58
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. 57
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial 54
Valutazione dei livelli di MMP-2, MPP-9 e dei loro inibitori nella iperlipemia combinata 53
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 53
Sitagliptin added to previously taken anti-diabetic agents on glycemic control and lipid profile 52
Valsartan improves plasma leptin in hypertensive obese patients 51
Vildagliptin Added to Metformin on β-Cell Function After a Euglycemic Hyperinsulinemic and Hyperglycemic Clamp in Type 2 Diabetes Patients 48
Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2 years study 48
Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months 47
Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes 45
The effects of canrenone in patients with metabolic syndrome 45
Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load 43
Totale 7.424
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.231
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.231
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021479 0 0 0 0 0 100 6 123 17 111 104 18
2021/2022366 0 0 18 3 3 3 2 25 21 2 58 231
2022/20231.364 130 93 1 91 161 150 0 90 571 17 40 20
2023/2024407 45 98 15 31 41 102 7 39 6 4 13 6
2024/20251.156 10 105 43 48 27 30 88 103 239 16 132 315
2025/20261.285 197 189 300 232 287 80 0 0 0 0 0 0
Totale 7.424